Retatrutide and trizepatide constitute a novel class of medications that bind to both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These combined receptor https://poppietvzu288698.educationalimpactblog.com/60117313/new-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide